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hepatitis (NASH) are increasingly relevant public health issues
owing to their close association with the worldwide epidemics
of diabetes and obesity. NAFLD/NASH is one of the most common
chronic liver diseases and increases the 5-year direct and indirect
health care costs by an estimated 26% [1]. Although evidence-
based clinical practice guidelines for this condition are badly
needed, currently not enough evidence is available to formulate
guidelines in an unbiased, responsible, and unequivocal way. This
position statement summarizes the proceedings of the 2009 EASL
Special Conference on NAFLD/NASH and proposes expert opinion
for different aspects of the clinical care of these patients.Deﬁnition and classiﬁcation of NAFLD/NASH
NAFLD designates a condition characterized by excessive fat
accumulation (steatosis). NASH deﬁnes a subgroup of NAFLD
where steatosis coexists with liver-cell injury and inﬂammation
(steatohepatitis).
Primary NAFLD/NASH is associated with insulin resistance (IR)
and its phenotypic manifestations. Secondary NAFLD/NASH is
rare in adults, is unrelated to insulin resistance or the metabolic
syndrome, and is due to a number of medical or surgical condi-
tions or drug intake. Historically, primary NAFLD/NASH required
the exclusion of other causes of liver disease (viral, autoimmune,
genetic, etc.) and a daily alcohol consumption 620 g in women
and 30 g in men, based on epidemiological studies showing that
alcohol-induced steatosis can occur above these thresholds [2].
Owing to its increasing prevalence and strong association with
the metabolic syndrome [3], it is now recognized that NAFLD/Journal of Hepatology 20
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that in some cases (chronic hepatitis C [4], hemochromatosis
[5], alcoholic liver disease [6]) this can exacerbate liver damage
[7]. This strongly argues for a change in nomenclature (such as
metabolic fatty liver disease and metabolic steatohepatitis)
which would drop the ‘‘negative” deﬁnition of ‘‘nonalcoholic”
and would recognize the likely causal role of IR in NAFLD/NASH.Epidemiology of NAFLD
The prevalence of NAFLD in the general population assessed by
ultrasonography is 20–30% in Europe [8,9] and the Middle East
[10], 15% in the Far East [11,12], and 16% in some studies of nor-
mal weight subjects without metabolic risk factors [2]. A similar
prevalence of 15–25% was documented histologically by older,
post-mortem studies [13,14]. A surprisingly high prevalence of
histological NAFLD has been described in apparently healthy liv-
ing liver donors: 12–18% in Europe [15,16] and 27–38% in the US
[15,17,18]. With sensitive technique such as MR spectroscopy,
34% of US adults have NAFLD [19]. Interestingly, 39% of newly
identiﬁed cases of chronic liver disease in a US survey had NAFLD
[20] which makes NAFLD/NASH one of the top causes of liver dis-
ease in Western countries.
Recent studies in tertiary-care centers, using current histolog-
ical deﬁnitions, have shown a surprisingly high prevalence of
NASH among NAFLD cases: 43–55% in patients with increased
aminotransferases [21,22], as high as 49% in morbidly obese
patients [23,24], and 67% in a subset of patients with incident
chronic liver disease [20]. In apparently healthy, living liver
donors, the prevalence of NASH ranges from 3% to 16% in Europe
[15,16] and from 6% to 15% in the US [15,17,18].Incidence
The incidence of primary NAFLD in Italy was estimated at 2/100/
year [25]; a Japanese study in a selected population reported10 vol. 53 j 372–384
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10/100/year [26]. Secondary NASH due to tamoxifen use was esti-
mated at 0.2/100 women/year [27].
Risk factors
The prevalence of NAFLD increases with age, is highest in males
between 40 and 65 years [28–31] and is higher in Hispanics and
lower in African-Americans [19,20]. Family members of subjects
with NAFLD are also at increased risk, independent of age and
BMI [32,33]. The commonest cause of NAFLD/NASH is primary
NAFLD, associated with IR and its phenotypic manifestations,
mainly overweight/obesity, visceral adiposity, type 2 diabetes,
hypertriglyceridemia and arterial hypertension [3,34,35]. A causal
association has been suggested by longitudinal studies showing a
chronological association between the progression of the meta-
bolic syndrome and the occurrence of NAFLD [36,37].Hepatic complications of NAFLD/NASH
Fibrosis and ﬁbrosis progression
In retrospective series from tertiary referral centers, bridging
ﬁbrosis is seen in 25–33% of NASH patients at diagnosis, includ-
ing cirrhosis in 10–15% [38]. NASH is by far the commonest cause
of ﬁbrosis and cirrhosis in patients with unexplained increased
ALT [21]. A micromorphometry study has suggested that NASH
has a ﬁbrotic potential similar to that of chronic hepatitis C after
adjustment for ﬁbrotic confounders [39]. Independent predictors
of ﬁbrosis are mainly age >45–50 and diabetes but also BMI >28–
30 kg/m2, hypertension, and the degree of IR [40–42]. Advanced
ﬁbrosis can coexist with normal aminotransferases [43,44].
Progression of ﬁbrosis has been demonstrated in retrospective
series, raising signiﬁcant methodological issues [45], in particular
whether the observed changes are within the range of what can
be expected from mere sampling variability [46]. Pooled data
[47–51] have shown that improvement occurs in only 21% of
patients with progression in 38% (with some progressing by
two stages or more or towards cirrhosis). The strongest predictor
of ﬁbrosis progression is necroinﬂammation on the initial biopsy
[52]. Rarely, progression of ﬁbrosis may occur in steatosis only
[51,53], presumably due either to concurrent non-speciﬁc inﬂam-
mation (insufﬁcient for a steatohepatitis diagnosis) [38] or to
missed lesions of steatohepatitis due to sampling variability.
End-stage NASH is an underecognized cause of cryptogenic
cirrhosis [54] mainly because steatosis and liver-cell injury can
disappear at this stage [39,55]. Past exposure to metabolic risk
factors (Table 1) is the key to diagnosis: at least one major risk
factor, being overweight or having diabetes, should be present
together with hypertension, dyslipidemia, or atheromatosis.
Using these criteria 30–75% of cryptogenic cirrhosis can be attrib-
uted to burned-out NASH [54,56–59].Table 1. Metabolic risk factors.
 Body mass index >25 kg/m2 and/or
 Waist circumference >94 cm in men, 80 cm in women (Caucasians)
 Arterial hypertension >135/85 mmHg
 Fasting serum glucose >6.1 mmol/L
 Serum triglycerides >1.7 mmol/L
 HDL-cholesterol <1 mmol/L (men); <1.3 mmol/L (women)
 Serum ferritin >350 lg/L
 First degree relatives of individuals with obesity and/or diabetes
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Cirrhosis complications. Liver failure is often (30–51%) the ﬁrst
presentation of patients with cirrhotic NASH [60,61] and occurs
after 7–10 years in 38–45% of cirrhotic cases [61,62] although
available data, all retrospective, are subject to lead-time bias.
Causes of death are liver failure, sepsis and variceal hemorrhage,
or hepatocellular carcinoma (HCC) [60,61]. The latter is often
diagnosed at a late stage [51,59,61,63], and may occasionally
occur in non-cirrhotic NASH [64]. Obese or diabetic patients have
an increased risk of HCC [65,66] even in association with other
chronic liver diseases [67,68].
Survival. Isolated steatosis does not increase overall or liver-
related mortality [51,69]. Long-term follow-up studies have
shown that NASH increases overall mortality by 35–85% com-
pared to the age and sex-matched general population
[51,70,71]. Liver-related mortality is increased 9–10-fold
[51,71] with cirrhosis an independent cause of death ranking
3rd vs. 13th in the general population [22,70,71]. This has been
conﬁrmed in pediatric series. Cardiovascular mortality is
increased two fold in NASH patients [51].
Liver transplantation. The proportion of patients with NASH
among those undergoing liver transplantation has steadily
increased over the recent past: from 0.1% between 1995 and
2000 to 3.5% in 2005 according to the UNOS database. Some of
the patients with cryptogenic cirrhosis should be added to these:
in one series one-third of these patients had histological signs of
NASH on a detailed histological review of the graft [56]. If half of
the patients with cryptogenic cirrhosis have burned-out NASH
(based on histology and exposure to metabolic risk factors), then
around 7% of liver transplants in the US are performed for NASH
[72]. Importantly, this is an underestimate of the proportion of
NASH progressing towards end-stage liver disease, as many
patients are no longer listed for liver transplantation because of
older age and associated comorbidities (mainly obesity, compli-
cations of diabetes, or malignancies) (see Tables 2–5).Extra-hepatic complications of NAFLD/NASH
Beyond damage to the liver, steatosis can also worsen and/or
induce IR, worsen glycemic control in patients with type 2 diabe-
tes, and predict subsequent development of the metabolic syn-
drome; it is also associated with increased cardiovascular risk
and events and with essential arterial hypertension. In other
endocrine disorders (polycystic ovary syndrome, hypothyroid-
ism, and panhypopituitarism) liver fat is merely related to under-
lying IR [72–76] without worsening it.
Liver fat and IR
There is a strong relationship between the amount of hepatic fat
and impaired insulin action, independent of global or regional
adiposity [77–79]. Excessive liver fat is associated with hepatic
but also muscle and adipose tissue IR [77,78] and it correlates
with all components of the metabolic syndrome [80,81]. Even
in healthy, normal weight individuals, liver fat is associated with
several features of IR, independent of BMI and intra-abdominal
obesity [80]. Therefore the hepatic fat content could identify IR
patients who might not be detected by a standard clinical evalu-
ation [77].0 vol. 53 j 372–384 373
Table 2. Epidemiological burden and risk factors.
 NAFLD/NASH is strongly associated with hepatic and systemic insulin resistance and is one of the hepatic complications of the insulin resistance syndrome.
 In the general population of industrialized countries, NAFLD/NASH is present in at least 20% of individuals. The prevalence is much higher in patients with metabolic
risk factors. NAFLD/NASH is currently the most frequent cause of incident chronic liver disease. It can coexist with other chronic liver diseases, with some data
showing that the association increases ﬁbrotic severity.
 The prevalence of NASH needs to be further deﬁned. In selected groups of healthy individuals, such as living related donors, the prevalence of NASH is as high as 3–
16%. In tertiary-care centers the proportion of histologically deﬁned NASH among NAFLD cases ranges from 40% to 55%.
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Although steatosis could be a mere consequence of IR, a causal
role in the genesis or worsening of IR has been suggested. Liver
fat reduces insulin clearance resulting in hyperinsulinemia, a fea-
ture of pre-diabetes [82]. Ultrasonography-diagnosed NAFLD
independently increases the risk of incident diabetes 2.5-fold.
Follow-up of NAFLD patients showed that steatosis precedes
full-blown complications of IR such as diabetes, arterial hyper-
tension or dyslipidemia [70], although this might not be indepen-
dent of the level of IR or of visceral adiposity [83]. In the general
population, high aminotransferases (a surrogate marker for
NAFLD) increased the long-term risk of incident diabetes, MS
and cardiovascular events [84]. Finally, on a fat-enriched diet,
steatosis and hepatic IR occurred earlier than peripheral IR sug-
gesting that IR in the liver is the primary defect in the develop-
ment of IR associated with obesity [85,86]. Therefore,
monitoring of NAFLD patients for metabolic complications and
therapeutic interventions aimed at reducing liver fat should be
evaluated in future studies.
Liver fat and diabetes control
Even at the stage of full-blown diabetes, the amount of liver fat
inﬂuences the severity of IR. Patients with type 2 diabetes and
steatosis have substantially more IR than those without steatosis
[87]; they also have more dyslipidemia and circulating inﬂamma-
tory markers [87]. Steatosis predicts, to a large extent, the
amount of insulin needed for glycemic control [88]. Future stud-
ies need to speciﬁcally address whether reducing liver fat
improves glycemic control in patients with type 2 diabetes.
NAFLD and cardiovascular disease (CVD)
Steatosis is associated with an increased prevalence [89,90] and
incidence of cardiovascular disease (non-fatal CVD events [91]
and CVD mortality [92]). The association is usually independent
of classic cardiovascular risk factors and, in a few cases, of the
metabolic syndrome [93,94]. In biopsy-proven NAFLD, steatosis
was associated with increased carotid artery intima-media thick-Table 3. Hepatic and extra-hepatic complications.
 Fibrosis progression is absent or minimal in isolated steatosis but has been docume
 End-stage NASH is a frequent cause of cryptogenic cirrhosis and should be diagnosed
lacking.
 NASH signiﬁcantly increases overall and liver-related mortality; cirrhosis, neoplasia
 Hepatocellular carcinoma can occur in cirrhotic NASH, thereby justifying monitorin
documented as this could impact on patient monitoring.
 Steatosis could be a contributing factor to insulin resistance. Steatosis predicts the d
vascular disease. All patients with NAFLD should be screened for cardiovascular risk
clustering of risk factors.
374 Journal of Hepatology 201ness and with carotid plaques [93]; moreover, signiﬁcant carotid
atherosclerosis occurred 5–10 years earlier in subjects with
NAFLD [95] than in those without. Biochemical surrogates of
NAFLD (GGT and ALT) predicted incident coronary artery disease,
stroke, and cardiovascular disease [94,96]. In diabetics NAFLD
further increases the risk of incident CVD and of diabetes compli-
cations [97,98]. Interestingly, endothelial dysfunction, an early
proatherogenic lesion is also associated with NAFLD, and is more
advanced in NASH than in bland steatosis [99].Diagnostic procedures and strategies
Non-invasive diagnosis of liver injury
Non-invasive markers for liver injury in NAFLD should be devel-
oped to facilitate screening for at-risk patients and for follow-up
of treated or untreated patients. Future trials should optimize
non-invasive diagnostic strategies so that the selection of
patients for drug therapy becomes possible even when liver
biopsy is not routinely available.
Serum markers for liver injury
Fibrosis. Proprietary tests validated on larger cohorts (FibroTest
[100], ELF panel [101], and FibroMeter fatty liver [102]) as well
as more simple clinical scores are available [40,103,104]. Most
can be used to distinguish between advanced and minimal/no
ﬁbrosis and a few provide a ﬁbrosis stage equivalent [100,102].
The diagnostic performance appears to be similar to that in hep-
atitis C. Additional full reports of independent validation are
needed.
Steatohepatitis. Diagnosing steatohepatitis is useful for prog-
nosis and management: it identiﬁes patients at risk for ﬁbrosis
progression and therefore justiﬁes more intensive counseling
on diet and lifestyle and allows the selection of patients for phar-
macological therapy [105]. Two serum markers, NASHTest [106]
and CK-18 [107] are validated on larger or on multicentric stud-
ies, and one in a smaller series, NASH Diagnostics [108]. CK-18 is
a promising marker but its diagnostic performance alone couldnted in retrospective series in more than one-third of NASH patients.
on past or present exposure to metabolic risk factors when histological signs are
, and cardiovascular disease are the main causes of death in NASH patients.
g strategies. Observations of HCC before the cirrhotic stage need to be further
evelopment of individual features of the metabolic syndrome and future cardio-
, and assessment should be periodically repeated (1–2 years) depending on the
0 vol. 53 j 372–384
Table 4. Diagnostic strategies and screening.
 Screening for NAFLD/NASH is not recommended in the general population; it is recommended in patients with metabolic risk factors and/or well characterized insulin
resistance.
 NASH is consensually deﬁned histologically by the association of steatosis, hepatocellular injury, and inﬂammation. Grading systems for longitudinal changes have
been proposed for follow-up and need to be validated in untreated and treated populations.
 There is a signiﬁcant need for the non-invasive quantiﬁcation of ﬁbrosis in order to facilitate screening of the large number of patients at risk. The association of serum
markers with an imaging method (elastometry) is recommended in order to restrict biopsy to indeterminate or discordant results or those predicted to have advanced
ﬁbrosis.
 A non-invasive diagnosis of steatohepatitis is warranted for the identiﬁcation of patients at risk of progression. The relevance of the non-invasive quantiﬁcation of
steatosis to patient management should be further studied.
JOURNAL OF HEPATOLOGYbe suboptimal [108] and it is confounded by the amount of ﬁbro-
sis [107].
Steatosis. Tests that predict steatosis would be useful if they
had a higher sensitivity than conventional imaging. Tests that
quantify steatosis might be clinically useful for monitoring early
changes induced by therapy and, although not proven, for pre-
dicting incident metabolic complications of steatosis or diabetes
control. Available tests cannot be compared for their diagnostic
performance as they have been validated against different stan-
dards: ultrasonography [109], liver biopsy [110], or MRI [82].
The FLI test predicts steatosis and could be useful for large-scale
screening instead of ultrasonography. SteatoTest [110] and the
NAFLD score [82] have a higher sensitivity than ultrasonography
and can also quantify steatosis. Only SteatoTest and the Fatty
Liver Index have been independently validated [109–112].
Imaging
Ultrasonography, computed tomography (CT), and MRI can iden-
tify histological steatosis higher than 20–30% [113] but not ste-
atohepatitis or the degree of ﬁbrosis [114]. Despite lower
sensitivity and speciﬁcity than CT, ultrasonography is an accept-
able ﬁrst-line screening procedure for NAFLD in clinical practice.
Quantiﬁcation of steatosis by ultrasonography [115] is not reli-
able since it is operator-dependent and has a low reproducibility.
MRI and MR spectroscopy reliably quantify steatosis and measure
regional fat depots. However, they are sequence dependent hence
standardization for sequence characteristics between centers is
necessary, and cost and availability are limiting [116,117]. Other
techniques, especially for quantifying ﬁbrosis, such as diffusion-
weighted imaging or MR elastography are promising but still
experimental.
In selected patients with NAFLD, measurement of liver stiff-
ness by transient elastography has a diagnostic performance for
ﬁbrosis close to that in hepatitis C [118,119] although the cut-offs
for ﬁbrosis stages are insufﬁciently deﬁned. Steatosis marginally
increases stiffness (by 1 kPa) [120] as does inﬂammatory activity
[121]. Although attractive because of its simplicity, immediate
results and reduced sampling error, there are signiﬁcant limita-
tions. BMI is a major predictor of failure rate (25% above 30 kg/
m2, 41% above 35 kg/m2) [122], usual values in non-obeseTable 5. Management of NAFLD/NASH.
 Weight-loss diet and exercise are ﬁrst-line therapeutic measures in all overweight
resistance-related comorbidities are not contraindicated in patients with NAFLD/NAS
steatosis.
 In addition to diet and lifestyle measures and depending of the ﬁbrosis stage, patien
slow progression of liver disease. To date there is some evidence for a beneﬁcial e
although the beneﬁt on ﬁbrosis is unproven.
 Treatment of NASH is an unmet medical need; placebo-controlled trials with histol
Post-approval, long-term safety assessment is essential due to associated comorbid
Journal of Hepatology 201healthy individuals without the metabolic syndrome can be as
high as 8 kPa [122], and increased liver stiffness can be seen
without ﬁbrosis in different conditions [123–125]. New probes
designed for obese individuals are currently being tested.
Measurement of IR
The gold standard for the quantitative measurement of insulin
sensitivity, the ‘‘euglycemic glucose clamp technique” [126], is
expensive and time-consuming, therefore surrogate markers are
useful. Waist circumference is well correlated with IR [127].
The product of glucose and insulin, calculated through the
Homeostasis Model Assessment (HOMA) [128] or the Quantita-
tive Insulin Sensitivity Check Index (QUICKI) [129] is a simple
method, although assay variability for insulin requires ‘‘normal”
values to be deﬁned for each laboratory. Other methods are based
on fasting values, mainly indicative of hepatic sensitivity, or on
the dynamics of glucose and insulin in response to an oral glucose
tolerance test [130,131], indicative of hepatic and peripheral
insulin sensitivity. Finally, insulin sensitivity on lipid metabolism
may be assessed in the fasting state as the ratio of triglyceride to
HDL-cholesterol levels [132].
Liver biopsy
The histological deﬁnition of adult NASH is based on a combina-
tion of three lesions (steatosis, hepatocellular injury, and inﬂam-
mation) within a characteristic topographical distribution
(mainly centrilobular, zone 3 of the acini). Steatosis is a prerequi-
site for the diagnosis of NAFLD, with the exception of cirrhotic
disease where it can be absent. The minimal threshold is 5% of
hepatocytes containing fat droplets. Signs of hepatocellular injury
are cytoplasmic clariﬁcation and ballooning of liver cells (a cardi-
nal, required feature) with or without acidophil bodies or spotty
necrosis [133]. Inﬂammation, either lobular or portal is composed
of mixed inﬂammatory cells and is of mild intensity. Both are part
of the NASH spectrum with portal inﬂammation present in
severe/advanced cases of NASH and lobular inﬂammation nearly
universal [134]. Polymorphonuclear inﬁltrates and Mallory–Denk
bodies, which can be seen in NASH, are not required for the diag-
nosis. Isolated steatosis or steatosis with lobular inﬂammationpatients with NAFLD and insulin resistance. Statins and other drugs for insulin
H, as the risk for hepatotoxicity does not seem to be increased in patients with
ts with NASH might beneﬁt from pharmacologic therapy in order to reverse or
ffect of glitazones and vitamin E on biochemical and histological parameters,
ogical end-points are recommended for registration purposes.
ities in many NASH patients.
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without signs of hepatocellular injury are both part of the wider
spectrum of NAFLD but do not qualify as NASH, mainly because of
their different outcome [53].
As in all chronic liver diseases, ﬁbrosis may or may not yet be
present and therefore it is not part of the deﬁnition of NASH. Peris-
inusoidal ﬁbrosis is a characteristic feature of NASH and current
staging systems incorporate bothperisinusoidal andportal ﬁbrosis
[135]. There is nowidely accepted grading classiﬁcation for NASH.
The NAS score is the unweighted sum of steatosis, ballooning and
lobular inﬂammation [135] andwas designed primarily to capture
treatment-induced histological changes. It can be used for grading
purposes, but it shouldnot be used for thediagnosis ofNASH [135].
All thesegradingandstaging systemshavenotyetbeensufﬁciently
validated for use by general pathologists.
A distinct histological pattern has been described in two spe-
ciﬁc patient populations. In children, NASH is characterized by
portal inﬂammation and ﬁbrosis, azonal steatosis and infrequent
ballooning or perisinusoidal ﬁbrosis [136]. In bariatric surgery
patients NASH is characterized by isolated portal ﬁbrosis and
azonal steatosis [42,133,137].
As in other chronic liver diseases sampling variability is a limita-
tion of liver biopsy in NAFLD [138]. Inﬂammatory lesions and bal-
looning are highly prone to sampling error as are ﬁbrosis and
steatosis which can result in misdiagnosis or understaging
[138,139]. There is no safe threshold for eliminating sampling vari-
ability[140];byanalogywithotherchronic liverdiseases,acore frag-
ment of a minimum of 15 and preferably 25 mm is desirable [139].Diagnostic strategies for NASH
Many individuals at risk for NAFLD/NASH seek medical attention
outside the Hepatology clinics and therefore it is important to
establish whether and in what settings screening or case ﬁnding
[141] for NASH is deemed necessary (see ‘‘Case ﬁnding”). Con-
versely, when patients with suspected NAFLD/NASH are
addressed for hepatological investigations, the procedures to be
performed need to be need to be deﬁned on an individualized
basis (see ‘‘Individual diagnostic strategies in clinical practice”),
in particular the indications for liver biopsy.
Case ﬁnding
Screening or case ﬁnding of NASH [141] aims at diagnosing
advanced liver disease, deﬁned as NASH with bridging ﬁbrosis
or cirrhosis. Beyond the prognostic information it provides this
may also change patient management including speciﬁc monitor-
ing strategies, a stricter enforcement of diet and lifestyle mea-
sures, or the use of liver-targeted pharmacologic therapy.
Premises:
(1) In the general population, there are currently insufﬁcient
data on the prevalence of NASH, NASH-related mortality
and on whether diagnosing NASH may change outcomes
and be cost-effective.
(2) NASH is strongly linked to IR and should be considered
part of the phenotypic complications of IR and the meta-
bolic syndrome. This implies that patients who come to
medical attention for IR (i.e. obesity, type 2 diabetes, dysl-
ipidemia polycystic ovarian syndrome, lipodystrophy, or
acanthosis nigricans) are at risk of NASH.376 Journal of Hepatology 201(3) Transaminases are not a sensitive test for NAFLD. However,
in patients with IR and increased ALT [142], the prevalence
of NASH and advanced ﬁbrosis [21] may be higher than in
the overall obese or diabetic population.
(4) Due to its high prevalence, NAFLD can occur in patients
with other chronic liver diseases. In chronic hepatitis C,
and possibly alcoholic liver disease and hemochromatosis,
NAFLD (or at least its risk factors) can worsen ﬁbrosis.
Based on the current literature and on what has been dis-
cussed during this conference, we suggest the following:
1. General population. Screening for advanced liver disease is not
recommended as per premise #1. Additional studies are
needed to delineate NAFLD risk factors, its potential as an
independent predictor of cardiovascular mortality and
NASH-related mortality.
2. In patients who come to medical attention because of IR (as
deﬁned in premises #2–3) case ﬁnding of advanced liver dis-
ease may be performed based on the high prevalence of NASH,
the adverse clinical outcomes and the potential changes in
patient management. Liver function tests and liver ultrasound
may be performed. In patients with increased ALT or with ste-
atosis at ultrasound we suggest that non-invasive methods to
evaluate ﬁbrosis be the ﬁrst-line procedure. At best, a serum
and an imaging procedure may be used. Liver biopsy may be
restricted to cases where both non-invasive methods suggest
advanced ﬁbrosis and to cases with indeterminate or discor-
dant results, thus deemed insufﬁcient to exclude advanced
ﬁbrosis. In patients with both increased ALT and steatosis at
ultrasound (at higher risk for advanced liver disease, premise
#3), liver biopsy could be the ﬁrst-line procedure until exten-
sive independent validation of non-invasive methods becomes
available.
3. Patients with chronic liver diseases other than NAFLD may be
screened for metabolic risk factors, IR, and steatosis at ultra-
sound. If all these are present, we suggest that liver biopsy
be performed to assess concurrent NAFLD, as data on non-
invasive methods in patients with concurrent liver diseases
are lacking.
4. During elective surgical procedures, such as anti-obesity sur-
gery (high risk of NASH and of unsuspected cirrhosis) and cho-
lecystectomy (shared risk factors between NAFLD and
cholelithiasis), we suggest that a liver biopsy be performed.
Individual diagnostic strategies in clinical practice
In patients referred for probable NAFLD to the hepatologist, liver
biopsy should be performed based on an individualized decision
rather than rigid guidelines. Liver biopsy provides both diagnostic
and prognostic information on ﬁbrosis and potential for progres-
sion. Liver biopsy should not be performed in patients with
recent weight change. In patients with stable weight and lifestyle,
a watchful period (4–6 months) is useful, aimed at enforcing diet
and lifestyle measures, unless previous structured attempts were
unsuccessful. If these measures result in weight loss with ALT
normalization and a reduction in IR, liver biopsy can be post-
poned while ALT and non-invasive markers of ﬁbrosis are moni-
tored. If not, liver biopsy should be considered after balancing the
risk for advanced ﬁbrosis (age, diabetes, degree of IR), patient0 vol. 53 j 372–384
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motivation, and competing comorbidities. Non-invasive ﬁbrosis
tests, ideally combining serum and imaging methods, may be
used to avoid the biopsy, when both suggest the absence of sig-
niﬁcant ﬁbrosis. New markers should be developed for early
identiﬁcation of patients at risk of progression.Pathogenesis
Is steatosis still the ﬁrst hit?
The ‘two hit’ model of NASH pathogenesis, suggested that the
ﬁrst ‘‘hit” is the development of steatosis sensitizing the liver to
the second ‘‘hit” – oxidative stress and cytokines – leading to
the development of necroinﬂammation and ultimately ﬁbrosis
and cirrhosis [143]. This hypothesis has been challenged by
recent data suggesting that mechanisms that can drive disease
progression can also induce steatosis. Oxidative stress [144]
and gut ﬂora/cytokines [145] can induce steatosis as well as necro-
inﬂammation and ﬁbrosis. Free Fatty Acids (FFA) can initiate
hepatocyte apoptosis [146] in addition to being esteriﬁed to tria-
cylglycerols. Endoplasmic stress can also lead to steatosis, oxida-
tive stress and apoptosis [147]. Since all these mechanisms are
important in obesity and IR, it would seem likely that they are
the true ‘‘ﬁrst hits” leading to increased hepatic FFA ﬂux and oxi-
dative-, ER-, and cytokine-mediated stress that result in both ste-
atosis and progressive liver damage in susceptible individuals.
Steatosis should therefore be considered part of the liver’s early
‘‘adaptive” response to stress, rather than a ﬁrst hit in disease
progression. Accordingly, while in some situations its severity
may act as a biomarker of ongoing injurious and ﬁbrotic mecha-
nisms resulting in disease progression, it should not be consid-
ered a therapeutic target. Instead attention should be focused
on the mechanisms of cellular injury and ﬁbrosis – the ‘‘second
hits”.
Mechanisms of ﬁbrosis
Numerous hepatic and extra-hepatic mediators might play a role
in the pathogenesis of ﬁbrosis in NAFLD. Hepatic mediators are:
(i) hepatocyte factors arising as a direct result of steatosis, hepa-
tocyte injury and apoptosis including IR, reactive oxygen species
and cytokines and (ii) Kupffer cell (KC), T cell, Hepatic stellate
cells (HSC), and other inﬂammatory cell-derived factors released
in response to hepatocyte injury and gut-derived bacterial prod-
ucts acting on toll-like pattern recognition receptors [148]. IR and
hyperglycemia may induce ﬁbrosis directly or via up-regulation
of connective tissue growth-factor or the generation of advanced
glycation end-products [149,150]. Both HSC and KCs engulf apop-
totic cells to generate pro-ﬁbrotic signals [151], with therapeutic
prospects for anti-apoptotic agents [152]. CD4 Th2-cell produc-
tion of IL-13 could contribute to ﬁbrogenesis [153]. Hepatic pro-
genitor cells can undergo an epithelial-mesenchymal transition,
partly triggered by Shh, a hedgehog ligand [154]. This results in
a pro-ﬁbrogenic myoﬁbroblast-like cell population, controlled
by the hedgehog pathway [155] and amenable to pharmacologi-
cal modulation [156]. With respect to signalling pathways
involved in ﬁbrogenesis, JNK1 signalling in KCs [157], NF-jB sig-
nalling in hepatocytes, KCs and HSC cells [158] and AMP-kinase
mediated signalling in HSC [159] are all potential therapeutic
targets.Journal of Hepatology 201Extra-hepatic mediators of ﬁbrosis in NAFLD, include the gut,
as a source of pro-inﬂammatory and pro-ﬁbrogenic bacterial
products including lipopolysaccharide, and visceral adipose tis-
sue as a source of adipcytokines – many of which have direct
pro-ﬁbrogenic effects on HSC including leptin, renin-angiotensin-
ogen and norepinephrine [160]. Equally important may be the
reduced secretion of adiponectin in obesity, an anti-steatotic,
anti-inﬂammatory and anti-ﬁbrotic adipocytokine [161]. At least
some of the anti-NASH effects of adiponectin may be exerted
through the activation AMP-kinase which is also a target for met-
formin and glitazones [162].Therapeutic management of NAFLD/NASH
Rationale for treatment choices
Therapy for NASH should prevent or reverse hepatic injury
induced by lipotoxicity. One strategy is to correct IR and hyperin-
sulinemia and to reduce fat mass, in particular visceral adiposity.
Weight loss and physical exercise, diet and lifestyle changes,
insulin-sensitizing agents and anti-obesity surgery are all aimed
at this objective. A second strategy is to prevent/reverse hepatic
cellular damage induced by lipotoxicity. This can be achieved
by inhibiting lipid peroxidation and oxidative stress, or through
the use of anti-inﬂammatory, anti-apoptotic or other hepatopro-
tective agents. These two strategies may be at best combined, and
future therapeutic research in NASH should focus on tailoring this
dual approach to the individual patient. The treatment and mon-
itoring of metabolic and cardiovascular comorbidities should be
implemented alongside the hepatologic management.
Non-pharmacologic measures
Weight loss, physical exercise, reduction of sedentary lifestyle
and dietary changes [163] should be implemented as ﬁrst-line
therapy, ideally on a long-term basis, in all patients with
NAFLD/NASH, regardless of the severity of their liver disease.
The best results are obtained with a multidisciplinary yet person-
alized approach [164]. The efﬁcacy of these measures should be
assessed after a 6-month period; if ineffective, additional thera-
peutic options such as pharmacologic therapy might then be con-
sidered. When earlier structured attempts had failed, additional
therapeutic options might be considered earlier. In patients with
steatosis alone or in young patients with NASH and no or mini-
mal ﬁbrosis, these measures are sufﬁcient, if efﬁciently imple-
mented and if clearly accompanied by a normalization of
aminotransferases.
Weight loss and dietary measures
The minimal amount of weight loss for improving NASH has not
been determined. A modest weight loss results in a signiﬁcant
reduction in liver fat despite minimal reduction in body fat
[165,166]. A 5–10% weight loss can sufﬁce for aminotransferase
normalization [167,168]. Data from a small series has determined
that a 9% weight loss improves steatosis signiﬁcantly and inﬂam-
mation marginally but not ﬁbrosis [169]. At present, aiming for a
weight loss of 7%, as proposed by International Societies on the
basis of an extensive body of literature, appears to be a reason-
able compromise in overweight and mildly obese patients.0 vol. 53 j 372–384 377
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The optimal type of weight-loss diet for NASH improvement is
not known, as large controlled trials comparing different diets
with histological end-points are lacking. A comparison of 4
weight-loss diets has shown that weight loss is similar regardless
ofmacronutrient composition [170], so ultimately, any type of diet
is likely to be beneﬁcial as long as the patient adheres to it. How-
ever long-term data indicate that only 15% of participants lose
more than 10% body weight, adherence drops after the ﬁrst few
months and most regain weight [170]. Behavioral therapy [164]
could help and should be implemented whenever the required
resources, which are considerable, are available. Regardless of
weight loss, the consumption of certain dietary constituents
appears to increase the risk of NASH/NAFLD and should be
avoided. High fructose corn syrup contributes to IR and NAFLD
[171], and therefore the consumption of soft drinks should be kept
to a minimum as should the consumption of industrial trans-fats
(present in many processed foods) which are also associated with
the development of NAFLD and hepatic inﬂammation [172–174].
Finally there is a reduction of the omega-3/omega-6 polyunsatu-
rated fatty acids ratio in the diet of NASH patients [175–177]
and experimental and limited clinical data suggest that increasing
this ratio by omega-3 dietary supplementation may lead to both
metabolic and histological improvement [178–181].
There is no evidence that alcohol abstinence is beneﬁcial for
patients with NAFLD/NASH. In fact studies have shown an inverse
association between modest wine drinking (less than a glass a
day) and biochemical [182,183], ultrasonographic [184] or histo-
logic [42] evidence of NAFLD/NASH with protective effects on
diabetes, IR, and features of the metabolic syndrome [185–187].
Physical exercise and sedentary time
Patients with NAFLD engage in less than half the amount of exer-
cise than age and sex-matched controls [112] and only 20–33% of
them meet current recommendations for physical activity [188].
Reasons for not exercising include fatigue [189], reduced cardio-
respiratory ﬁtness [188,190], weight-related arthrosis, cardiovas-
cular disease, and psychological factors [191]. Physical activity
correlates inversely with intra-hepatic fat [192], increases insulin
sensitivity [193], and reduces abdominal fat [194]. In obese indi-
viduals, short-term (4 weeks) aerobic exercise reduces hepatic fat
and visceral adiposity even without a change in body weight or
dietary intake [195]. Longer-term exercise (3 months) improves
cardiorespiratory ﬁtness, IR and liver enzymes independent of
weight loss [196]. Physical activity targets derived from diabetes
prevention trials and supported by International Societies could
be applied to adult patients with NAFLD/NASH: at least
150 min per week of moderate-intensity physical activity (brisk
walking) and at least 75 min per week of vigorous-intensity
physical activity (jogging), in addition to muscle strengthening
activities twice a week. However, individualized counseling is
preferable and even limited physical activity is better than none,
therefore any increase over baseline is preferable. Avoiding sed-
entary time outside the periods of physical exercise is equally
important [197].
Bariatric surgery
In some bariatric surgery series massive weight loss has beneﬁ-
cial effects on steatohepatitis [198], and ﬁbrosis [198–200], an
overall improvement which was dependent on the correction of378 Journal of Hepatology 201IR [201], although some controversy exists regarding the long-
term histological beneﬁts [202]. However, only highly selected
morbidly obese patients are eligible for anti-obesity surgery. If
otherwise indicated, anti-obesity surgery should be encouraged
from the perspective of liver disease, especially in patients with
advanced ﬁbrotic NASH. We suggest that a systematic liver
biopsy during surgery be performed because liver injury is
asymptomatic even with advanced ﬁbrosis or cirrhosis, steato-
hepatitis is frequent [23] and there is a high probability of rever-
sal of liver lesions.
Pharmacologic therapy
Indications. Pharmacologic therapy directed at the correction of
concurrent metabolic disorders (statins, antihypertensive
agents, antidiabetic drugs, etc.) should be given as needed, as
NAFLD does not increase hepatotoxicity or other side effects
of these drugs. Pharmacologic therapy speciﬁcally aimed at
improving the liver condition is indicated based on the poten-
tial for disease progression, the severity of ﬁbrosis, and the
potency of drugs to reverse or stop the progression of liver
damage.
Steatosis. Pharmacologic therapy is not warranted for bland
steatosis. Efforts should aim at preventing extra-hepatic com-
plications of steatosis. Annual hepatic monitoring is warranted.
Indeed, the initial liver biopsy could have missed lesions of ste-
atohepatitis due to sampling error. Alternatively, additional
metabolic risk factors can occur or worsen during follow-up
(weight gain, occurrence of diabetes or dyslipidemia), which
might increase the individual’s risk of developing steatohepati-
tis. Optimal monitoring includes non-invasive follow-up of
ﬁbrosis (ideally serum markers together with elastometry),
aminotransferases and markers of IR (fasting insulin and HOMA
score) and could be done in a primary care setting. If there is
ﬁbrosis progression on repeated non-invasive assessment,
worsening of metabolic risk factors and/or an otherwise unex-
plained increase in serum aminotransferases, a repeat liver
biopsy, at least 5 years after the baseline biopsy, may be
indicated.
Steatohepatitis (NASH). The aim of therapy is to prevent pro-
gression of liver ﬁbrosis towards cirrhosis and/or decompensa-
tion of cirrhosis. Given the current understanding of natural
history, NASH with no or minimal ﬁbrosis (stages 0 or 1) does
not require hepatic-targeted pharmacologic therapy. Liver-
directed treatment could be indicated in NASH with intermedi-
ate ﬁbrosis (Kleiner stage 2), high histological activity and risk
factors for advanced ﬁbrosis (age >50, diabetes, arterial hyper-
tension or severe IR). NASH with bridging ﬁbrosis (stage 3) and
maybe, cirrhosis requires hepatic treatment. Annual non-inva-
sive monitoring of ﬁbrosis is warranted for all stages of disease
whether or not patients are on hepatic treatment. Until non-
invasive markers are fully validated, consideration should be
given to interval repeat biopsies in patients with stages 2 or
3 disease to identify those patients who have progressed to cir-
rhosis who will require surveillance for the development of
varices and HCC.
Speciﬁc liver-directed therapy
There are no approved medications for NASH, therefore the drugs
discussed below should still be considered as experimental.0 vol. 53 j 372–384
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Glitazones are the only compounds having consistently shown
some beneﬁt in patients with NASH. Five randomized controlled
trials are available [203–207], which are heterogenous for drugs
and dosages, duration of treatment, categories of patients included
and histological outcomes [208]. Almost all studies have shown a
reduction in aminotransferase levels and steatosis and most an
improvement in liver-cell injury and inﬂammation. None of them
have shown a convincing beneﬁt for ﬁbrosis. Longer treatment,
up to 3 years, does not confer additional histological beneﬁt as
most of the improvement occurs in the ﬁrst year [209]. In a
larger, multicentric US trial [207] pioglitazone signiﬁcantly
improved all histological aspects of liver injury (including resolu-
tion of steatohepatitis) more often than placebo, but not ﬁbrosis.
However, pioglitazone failed to achieve a predetermined primary
composite end-point. Metformin had a beneﬁcial effect on ALT in
some [210,211] but not all [212] studies. Results on histology are
conﬂicting [211,213] with controlled studies showing no beneﬁt
[214,215] possibly because the limited anti-steatogenic effect
and small or no increase in adiponectin, at least in the short-term
[216]. Other insulin-sensitizing agents such the weight-loss agent
orlistat [169,217] seem ineffective. Ursodesoxycholic acid alone
did not show a consistent biochemical and histological beneﬁt
at the dose of 13–15 mg/kg [218,219]; higher doses (30 mg/kg)
induced a signiﬁcant reduction in aminotransferase values,
although it is uncertain whether this translates into histological
improvement [220]. There are several small negative trials with
vitamin E [211,221,222]; however, in a larger randomized trial
800 IU/day improved all histological lesions except for ﬁbrosis
[207]. In a small randomized trial, the combination of vitamin E
and ursodesoxycholic acid (13–15 mg/kg) induced biochemical
and histological improvement [223]. Other hepatoprotective
agents such as betaine [224], pentoxiﬁlline [225], or probucol
were not convincingly effective in randomized trials. Only preli-
minary uncontrolled trial results are available for omega-3 poly-
unsaturated fatty acids and sartans. Given the current data and
what has been discussed during this conference, a recommenda-
tion for pharmacologic therapy of NASH could be either a 1–
2 year course of therapy with glitazones or vitamin E, preferably
in association with high-dose ursodesoxycholic acid.Guidelines for future therapeutic trials
Since there are no approved drugs for NASH development pro-
grams should be designed to meet relevant but also achievable
end-points. For drug approval, histological end-points such as
improvement in the NAS score and/or disappearance of steato-
hepatitis are relevant, as steatohepatitis and necroinﬂammatory
lesions are clearly associated with progression of the disease
[52]. These end-points are most likely achievable with 1 or 2 year
trials with reasonably large sample sizes. Larger and longer trials
would be necessary for documenting an impact on ﬁbrosis or a
reduction in incident cirrhosis or other hard end-points; there-
fore these end-points should be requested not for registration
but for outcome trials, an important but not an initial step in
the registration process. The type of patients to be included in
registration trials are those with NASH regardless of ﬁbrosis
stage, as steatohepatitis is a potentially progressive condition in
regards to liver ﬁbrosis. A key aspect will be the thorough assess-
ment for safety, as these drugs will be given to patients with
numerous comorbidities and concomitant treatments. Therefore
a long-term commitment from drug companies for carefullyJournal of Hepatology 201planned, post-marketing studies should be requested as part of
the development program for all approved drugs.Conclusion
NASH is an increasingly prevalent liver disease which increases
overall and liver-related mortality. Steatosis might worsen insu-
lin resistance and predict the development of metabolic or car-
diovascular complications. Non-invasive diagnostic strategies
should be developed particularly for the screening of the large
number of individuals with metabolic risk factors. Collaboration
between hepatologists and specialists in the endocrine, nutri-
tional, and cardiology ﬁelds should be encouraged to optimize
clinical management. Research efforts should be enhanced
through a multinational European collaborative research
program.
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